ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 329

Factors Associated with Worsening Serum Vitamin D Deficiencies in Japanese Patients with Rheumatoid Arthritis: Results from the IORRA Cohort Study

Masanori Nakayama1, Takefumi Furuya1, Eisuke Inoue2, Eiichi Tanaka1, Katsunori Ikari1, Ayako Nakajima1, Atsuo Taniguchi1 and Hisashi Yamanaka1, 1Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 2Division of Medical Informatics, St. Marianna University School of Medicine, Kawasaki, Japan

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: observation, registry and rheumatoid arthritis (RA), Vitamin D

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 5, 2017

Title: Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: In 2011, we evaluated serum vitamin D levels in Japanese patients with rheumatoid arthritis (RA) and reported the prevalence of, and factors associated with, vitamin D deficiency [1]. Limited data exist in the literature concerning factors that predispose patients with RA to a worsening vitamin D deficiency. The aim of this study was to investigate predictive factors for a worsening vitamin D deficiency using our Institute of Rheumatology Rheumatoid Arthritis (IORRA) cohort.

Methods: Established in the year 2000, the IORRA cohort is a single institute-based large cohort of Japanese RA patients. Over 120 publications have described various characteristics of Japanese patients with RA using this large cohort. In 2013, fresh serum from those patients who participated in our first vitamin D study in 2011 was evaluated for 25-hydroxyvitamin D [25(OH)D] levels via radioimmunoassay. A vitamin D deficiency was defined as serum 25(OH)D levels <20 ng/mL. To determine the predictive factors of a worsening vitamin D deficiency over a 2-year period, multivariate logistic regression analyses were used.

Results: Among the 2534 patients with RA who participated in our vitamin D studies in 2011 and 2013 (2179 women and 355 men; mean age 59.6 years), the mean (± standard deviation) serum 25(OH)D level was 18.0 (±5.8) ng/mL, and the prevalence of vitamin D deficiency was 68.2% in 2013. Via multivariate analysis, younger age, female gender, and a high score for the Japanese version of the Health Assessment Questionnaire disability index (J-HAQ-DI) were significantly associated with vitamin D deficiency (P<0.05). Serum vitamin D levels decreased by >5 ng/mL over the 2 years from 2011 to 2013 in 224 (8.8%) patients. For that subset of patients, a multivariate analysis revealed, younger age, female gender, bisphosphonate disuse, and higher baseline serum 25(OH)D levels were significantly associated with the decrease in vitamin D levels over the two years (P<0.05) (Table).

Conclusion: In Japanese patients with RA, younger age, female gender, bisphosphonate disuse, and a high baseline serum 25(OH)D level appear to be associated with serum vitamin D levels that worsen over time.

Table:Factors associated with a further decrease in serum 25(OH)D levels in Japanese patients with RA from 2011 to 2013.

Variables

Odds ratio

(95% CI)

P

Age

0.981 (0.964-0.999)

0.0338

Female gender

2.190 (1.100-4.360)

0.0254

Bisphosphonate use

0.431 (0.201-0.925)

0.0308

Baseline serum vitamin D levels

1.310 (1.27-1.35)

<0.0001

Reference: 1) Clin Rheumatol. 2013; 32: 1081-7.


Disclosure: M. Nakayama, Bristol-Myers Squibb, 8; T. Furuya, UCB, 8,Bristol-Myers Squibb, 8,Takeda, 8,Eisai, 8,Chugai, 8,Pfizer Inc, 8,Ono, 8,Asahi Kasei, 8; E. Inoue, Merck Serono Co., Ltd., 8; E. Tanaka, Abbvie, 8,Ayumi, 8,Bristol-Myers Squibb, 8,Chugai, 8,Eisai, 8,NIppon Kayaku, 8,Pfizer Inc, 8,Takeda, 8,UCB, 8; K. Ikari, Bristol-Myers Squibb, 8,Abbvie, 8,Eisai, 8,Asahi Kasei, 8,Asttelas, 8,Chugai, 8,Hisamitsu, 8,Janssen Pharmaceutica Product, L.P., 8,Taisho Toyama, 8,Takeda, 8,Santen, 8,Tanabe-Mitsubishi, 8,Kaken, 8; A. Nakajima, Nippon-Kayaku, 5,Bristol-Myers Squibb, 8,Chugai, 8,Novartis Pharmaceutical Corporation, 8,Pfizer Inc, 8,Siemens, 8,Tanabe-Mitsubishi, 8; A. Taniguchi, Pfizer Inc, 8; H. Yamanaka, MSD, 2,Astellas, 2,AbbVie, 2,BMS, 2,Kaken, 2,UCB, 2,Ono, 2,Ayumi, 2,Eisai, 2,Daiichi-Sankyo, 2,Takeda, 2,Tanabe-Mitsubishi, 2,Chugai, 2,NIpponshinyaku, 2,Pfizer Inc, 2,Pfizer Inc, 8,YL biologics, 8,Takeda, 8,NIpponkayaku, 8,Chugai, 8,Tanabe-Mitsubishi, 8,Daiichi-Sankyo, 8,Astellas, 8.

To cite this abstract in AMA style:

Nakayama M, Furuya T, Inoue E, Tanaka E, Ikari K, Nakajima A, Taniguchi A, Yamanaka H. Factors Associated with Worsening Serum Vitamin D Deficiencies in Japanese Patients with Rheumatoid Arthritis: Results from the IORRA Cohort Study [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/factors-associated-with-worsening-serum-vitamin-d-deficiencies-in-japanese-patients-with-rheumatoid-arthritis-results-from-the-iorra-cohort-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/factors-associated-with-worsening-serum-vitamin-d-deficiencies-in-japanese-patients-with-rheumatoid-arthritis-results-from-the-iorra-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology